Search

Search
Generic filters
Machine learning creates opportunity for new personalized therapies

Machine learning creates opportunity for new personalized therapies

Researchers at the University of Michigan Rogel Cancer Center have developed a computational platform that can predict new and specific metabolic targets in ovarian cancer, suggesting opportunities to develop personalized therapies for patients that are informed by the genetic makeup of their tumors. The study appeared in Nature Metabolism.
Breakthrough brings potential glioblastoma drug into focus

Breakthrough brings potential glioblastoma drug into focus

Glioblastoma, the most common cancerous brain tumor in adults, is an aggressive disease – patients survive an average of just 15 months once they are diagnosed. Despite more than two decades of research on the causes and treatments of glioblastoma, that prognosis has hardly improved.
Similar medications cost more for humans compared to pets

Similar medications cost more for humans compared to pets

In a research letter published in JAMA Internal Medicine, University of Minnesota researchers compared the prices of 120 medications commonly used in humans and pets. The authors found the price of human medications was generally higher than the price of pet medications with the same ingredients at common human-equivalent doses.
2nd Annual Next Generation Pharmaceutical Cleanrooms Conference

2nd Annual Next Generation Pharmaceutical Cleanrooms Conference

5 – 6 October 2022, London, United Kingdom.
SAE Media Group are pleased to announce the 2nd Annual Next Generation Pharmaceutical Cleanroom Conference. An event that focuses on cleanroom technology in the pharmaceutical industry, the conference will serve to bridge that gap between the two areas while simultaneously providing a unique selling point.
Pfizer to supply Global Fund up to 6 million PAXLOVID™ treatment courses for low-and-middle-income countries

Pfizer to supply Global Fund up to 6 million PAXLOVID™ treatment courses for low-and-middle-income countries

Pfizer Inc. (NYSE: PFE) announced today an agreement to supply up to six million treatment courses of its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) to Global Fund as part of its COVID-19 Response Mechanism (C19RM). The C19RM has been the primary channel for providing grant support to low- and middle-income countries to purchase COVID-19 tests, treatments, personal protective equipment and critical elements of health systems strengthening.
Shutting down backup genes leads to cancer remission in mice

Shutting down backup genes leads to cancer remission in mice

The way that tumor cells enable their uncontrolled growth is also a weakness that can be harnessed to treat cancer, researchers at the University of Michigan and Indiana University have shown.

Their machine-learning algorithm can identify backup genes that only tumor cells are using so that drugs can target cancer precisely.

Bird’s enzyme points toward novel therapies

Bird’s enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs.

The species of bird is the only one known to naturally produce an enzyme able to generate a noncanonical amino acid; that is, one not among the 20 necessary to encode most proteins.

WHO strongly advises against antibody treatments for COVID-19 patients

WHO strongly advises against antibody treatments for COVID-19 patients

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in The BMJ.

These drugs work by binding to the SARS-CoV-2 spike protein, neutralising the virus’s ability to infect cells.

Back to Top
Product has been added to your cart